XML 54 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Description of Business (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Oct. 31, 2024
product
Apr. 30, 2024
USD ($)
shares
Mar. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
product
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Subsidiary, Sale of Stock [Line Items]            
Loss from operations       $ 34,411 $ 49,233 $ 65,330
Net loss       50,420 61,685 74,412
Net cash used in operating activities       17,999 34,008 $ 84,912
Cash and cash equivalents       86,952 62,838  
Accumulated deficit       $ 609,399 $ 558,979  
Symatese Europe Agreement            
Subsidiary, Sale of Stock [Line Items]            
Regulatory approval, number of products | product 3     4    
Symatese U.S. Agreement            
Subsidiary, Sale of Stock [Line Items]            
Expected regulatory approval, number of products | product       2    
Follow-on Offering            
Subsidiary, Sale of Stock [Line Items]            
Sale of stock, number of shares issued in transaction | shares     3,554,000      
Offering price per share (in dollar per share) | $ / shares     $ 14.07      
Aggregate net proceeds from stock offering     $ 46,794      
Over-Allotment Option            
Subsidiary, Sale of Stock [Line Items]            
Sale of stock, number of shares issued in transaction | shares   318,100 533,100      
Aggregate net proceeds from stock offering   $ 4,169        
Granted options, exercisable period     30 days